Blocking TREM-1 signaling has been explored as a potential approach to the treatment of inflammation-associated disorders, including sepsis, rheumatoid arthritis, and retinal neovascularization, as well as cancer (13, 36, 37, 39, 45). This evidence concerns the gene TREM1 and rheumatoid arthritis.